Aptar Pharma extends its child-resistant nasal pump manufacturing capabilities in North America
As of today, all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s child-resistant feature.
Aptar Pharma has announced the installation of manufacturing capacity for its child-resistant and senior-friendly classic nasal pump in their Congers, NY site.
Effective April 2017, a new assembly machine for Aptar Pharma’s Child-resistant (CR) feature for nasal sprays was transferred from Aptar Pharma’s plant in Southern Germany to Congers, NY. This represents an important step in Aptar Pharma’s history, bringing its manufacturing capacity closer to the target market for which this pump has been successfully established.
Aptar Pharma’s child-resistant technology platform was developed primarily for the US market when, in 2012, the US Consumer Product Safety Commission (CPSC) issued a rule requiring CR packaging for any over-the-counter or drug product containing the equivalent of 0.08 mg or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.
p>Less than 2 years after the rule’s announcement, Aptar Pharma introduced its newly-engineered child-resistant/senior-friendly nasal spray pump to the US market, which successfully matched the CPSC requirements.Aptar Pharma’s child-resistant feature for nasal sprays effectively combines child-resistance and senior-friendliness with its intuitive and widely-accepted squeeze-and-turn technology. The positive market feedback and increasing demand for the child-resistant feature over the last 2 years demonstrates that Aptar Pharma’s CRSF technology is the best-in-class solution available on the US market. As of today, all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s child-resistant feature.
According to Alex Theodorakis, President Aptar Pharma North America: “We are pleased to welcome the arrival of Aptar Pharma’s child-resistant assembly machine to our recently expanded Congers, NY manufacturing site. This added manufacturing capacity enables us to offer the production of this key child-resistant/ senior-friendly feature to our customers domestically. Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance